Noticias de FATE_US

Noticias del mercado

Últimas noticias sobre FATE_US — 209 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: FATE_US ✕ 209 resultados
21/05/2026 FATE_US — Investing.com Canada ES ← EN
Fate Therapeutics presentará datos de células CAR T en conferencias médicas

Fate Therapeutics to present CAR T-cell data at medical conferences

21/05/2026 FATE_US — GlobeNewswire ES ← EN
Fate Therapeutics anuncia presentaciones en 2026 ASCO y

Fate Therapeutics Announces Presentations at 2026 ASCO and

21/05/2026 FATE_US — Investing.com UK
Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares By Investing.com
21/05/2026 FATE_US — The Legal Advocate
Fate Therapeutics (FATE) Surges 14%: Key Levels to Watch - Unusual Call Volume
21/05/2026 FATE_US — The Manila Times
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
21/05/2026 FATE_US — GlobeNewswire
Fate Therapeutics Announces Presentations at 2026 ASCO and
21/05/2026 FATE_US — Investing.com
Fate Therapeutics to present CAR T-cell data at medical conferences
21/05/2026 FATE_US — newsline.com
Fate Therapeutics (FATE) Surges 14%: Key Levels to Watch - Overnight Profile
21/05/2026 FATE_US — Investing.com
Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares By Investing.com
21/05/2026 FATE_US — Stock Titan
Fate Therapeutics (FATE) officer sells 25,590 shares in tax-related transaction
21/05/2026 FATE_US — Investing.com
Fate Therapeutics to present CAR T-cell data at medical conferences
21/05/2026 FATE_US — Stock Titan
Fate Therapeutics (FATE) CEO executes 28,946-share sell-to-cover tax sale
21/05/2026 FATE_US — Investing.com
Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares
21/05/2026 FATE_US — Stock Titan
Off-the-shelf CAR T trials in cancer and autoimmune at 2026 ASCO, EULAR
21/05/2026 FATE_US — Yahoo Finance
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
21/05/2026 FATE_US — newsline.com
Fate Therapeutics (FATE) Surges 14%: Key Levels to Watch - Symmetrical Triangle
20/05/2026 FATE_US — Investing.com ES ← EN
Jefferies lanza acciones de Fate Therapeutics con calificación de compra por potencial autoinmune

Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential

20/05/2026 FATE_US — Stock Titan
[144] FATE THERAPEUTICS INC SEC Filing
20/05/2026 FATE_US — TradingView
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
20/05/2026 FATE_US — Stock Titan
[144] FATE THERAPEUTICS INC SEC Filing

Página 3 de 11

keyboard_arrow_up